Summary
We studied 15 hyperprolactinemic women to evaluate possible modifications of bone mineral content after pharmacological treatment. Patients received a dopamine agonist (bromocriptine) for six months after which there was a significant decrease of prolactin plasma levels (P<0.01) and a significant increase of bone mineral content (F<0.05)
This is a preview of subscription content, log in via an institution to check access.
References
Frantz AG (1978) Prolactin. Physiol. Med. 298: 201–207.
Klibansky A, Neer RM, Beitins JZ, Ridgway CE, Zervas NT, Mc Arthur JW (1980) Decreased bone density in hyperprolactinemic women. N. Eng. J. Med. 303:1511–1514.
Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia.
Girardello R, Corghi E, Caraceni MP, Motta T, Maraschini C, Ortolani S (1982) Reduced bone mineral mass in hyperprolactinemic women. Mineral Metab. Res. Italy 3:225–228.
Jacobs H, Franks S, Murray M, Hull G, Steele S, Nabarro J (1976) Clinical and endocrine features of hyperprolactinemic amenorrhea. Clin. Endocrinol. 5:439.
Castro HJ, Caro JF, Kim HJ, Glennon JA (1980) Effects of parathyroid hormone infusion and primary hyperparathyroidism on serum prolactin in man. J. Clin. Endocrinol. Metab. 51:397–398.
Adams ND, Garthwaite TL, Gray RW, Thad CH, Lemann J Jr (1979) The interrelationship among prolactin, 1, 25-Dihydroxyvitamin D, and parathyroid hormone in humans. J. Clin. Endocrinol. Metab. 49:628–630.
Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-Dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107,1:81–84.
Matsumoto T, Horiuchi N, Suda T, Takalashi H, Sdhimazawa E, Ogata E (1979) Failure to demonstrate stimulatory effest of prolactin on vitamin D metabolism in vitamin D-deficient rats. Metabolism 28:925–927.
Corghi E, Cecchettin M, Quinzanini M, Caraceni MP, Motta T, Ortolani S, Polli EE (1983) Vitamin D metabolites in hyperprolactinemia. In: Caniggia A (ed) Proceedings of 4th international congress on calciotropic hormones. Medical System Genova, p. 75.
Brown DJ, Spanos E, Mac Intyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. Br. Med. J. 20:277–278.
Isaac R, Merceron R, Caillens G, Raymond JP, Ardoillou R (1980) Effects of calcitonin on basal and thyrotropin-realising hormone stimulated prolactin secretion in man. J. Clin. Endocr. 50:1011
Ziliotto D, Luisetto G, Heynen G, Francia G, Gastaldo M, Cecchini M (1981) Decrease in serum prolactin levels after acute intravenous injection of salmon calcitonin in normal subjects. Horm. Metab. Res. 13:64.
Olgiati VR, Guidobono F, Luisetto G, Netti C, Bianchi C, Pecile A (1981) Calcitonin inhibition of phisiological and stimulated prolactin secretion in rats. Life Sci. 29:585.
Olgiati VR, Netti C, Guidobono F, Pecile A (1982) High sensitivity to calcitonin of prolactin-secreting control in lactating rats. Endocrinology 111:641.
Clementi G, Nicoletti F, Patacchioli F, Prato A, Patti F, Fiore CE, Matera M, Scapagnini U (1983) Hypoprolactinemic action of calcitonin and the tuberoinfundibular dopaminergic system. J. Neurochem. 40:885–886.
Rubinacci A, Scotti A, Tessari L (1983) The effect of long-term treatment with L-Dopa on bone mass of post-menopausal women. Calcif. Tissue Int. 35 (Suppl 1) A4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caraceni, M.P., Corghi, E., Ortolani, S. et al. Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37, 687–689 (1985). https://doi.org/10.1007/BF02554932
Issue Date:
DOI: https://doi.org/10.1007/BF02554932